Salt intake and depletion increase circulating levels of endogenous ouabain in normal men

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 290, Issue 3, 2006, Pages

  Manunta, Paolo ^a,b   Hamilton, Bruce P ^a   Hamlyn, John M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiac glycosides; Circulation; Hypertension; Inhibitor; Sodium; Sodium pump

Indexed keywords

ALDOSTERONE; HYDROCHLOROTHIAZIDE; OUABAIN; SODIUM CALCIUM EXCHANGE PROTEIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; DIET SUPPLEMENTATION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SALT INTAKE; SODIUM BALANCE; SODIUM DEPLETION; SODIUM EXCRETION; STATISTICAL ANALYSIS; ADAPTATION; BLOOD; BLOOD PRESSURE; EATING; METABOLISM; PHYSIOLOGY; REFERENCE VALUE; SODIUM RESTRICTION; URINE;

ADAPTATION, PHYSIOLOGICAL; ADULT; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; EATING; HUMANS; MALE; OUABAIN; REFERENCE VALUES; SODIUM CHLORIDE, DIETARY;

EID: 33645395096     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00648.2005     Document Type: Article

References (53)

1. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, and Anderson DE. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 31: 296-305, 1996.
2. Balzan S, Nicolini G, Lervasi A, Di Cecco P, and Fommei E. Endogenous ouabain and acute salt loading in low-renin hypertension. Am J Hypertens 18: 906-909, 2005.
3. Besseghir K and Rock-Ramel F. Renal excretion of drugs and other xenobiotics. Renal Physiol 10: 221-241, 1987.
4. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol Cell Physiol 232: C165-C173, 1977.
5. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, and Gann DS. Ouabain is secreted by the adrenal gland in the awake dog. Am J Physiol Endocrinol Metab 264: E413-E419, 1993.
6. Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, and Hamlyn JM. Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 17: 944-950, 1991.
7. Cassels BK. Analysis of a Maasai arrow poison. J Ethnopharmacol 14: 273-281, 1985.
8. Dostanic I, Paul RJ, Lorenz JN, Theriault S, Van Huysse JW, and Lingrel JB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol 288: H477-H485, 2005.
9. Eichorn EJ, McGhie AL, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, and Grayburn PA. Effects of bucindolol on neurohumoral activation in congestive heart failure. Am J Cardiol 67: 67-73, 1991.
10. Fedorova OV, Doris PA, and Bagrov AY. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens 20: 581-591, 1998.
11. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, and Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 30: 886-896, 1997.
12. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, Corsico N, and Bianchi G. PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 285: 83-94, 1998.
13. Fujita T and Ito Y. Salt loads attenuate potassium-induced vasodilation of the forearm vasculature in humans. Hypertension 21:772-778, 1993.
14. Goto A, Yamada K, Ishii M, and Sugimoto T. Digitalis-like activity in human plasma: relation to blood pressure and sodium balance. Am J Med 89: 420-426, 1990.
15. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, and Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52: 584-594, 1972.
16. Haddy FJ and Overbeck HW. The role of humoral agents in volume-expanded hypertension. Life Sci 19: 935-947, 1976.
17. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, and Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 88: 6259-6263, 1991.
18. Hamlyn JM, Laredo J, Shah JR, Lu ZR, and Hamilton BP. 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann NY Acad Sci 986: 685-693, 2003.
19. +-ATPase associated with essential hypertension. Nature 300: 650-652, 1982.
20. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, and DuCharme DW. Development of an immunoassay for endogenous digitalis factor. Hypertension 17: 936-943, 1991.
21. Ito S, Koren G, and Harper PA. Handling of digoxin and ouabain by renal tubular cells (LLC-PK1). J Pharmacol Exp Ther 262:109-113, 1992.
22. 2+ exchanger type-1 in vascular smooth muscle. Nat Med 10: 1193-1199, 2004.
23. Kumar R, Yankopoulos NA, and Abelmann WH. Ouabain-induced hypertension in a patient with decompensated hypertensive heart failure. Chest 63: 105-108, 1973.
24. Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis and blood pressure electrolyte homeostasis. N Eng J Med 313: 1330-1340, 1985.
25. Laredo Laredo J AII, Hamilton BP, and Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 135: 794-797, 1994.
26. Ludens JH, Clark MA, Kolbasa KP, and Hamlyn JM. Digitalis-like factor and ouabain-like compound in plasma of volume-expanded dogs. J Cardiovasc Pharmacol 22 Suppl 2: S38-S41, 1993.
27. Ludens JH, Clark MA, Robinson FG, and DuCharme DW. Rat adrenal cortex is a source of circulating ouabainlike compound. Hypertension 19: 721-724, 1992.
28. Luft FC, Grim CE, Willis LR, Higgins JT, and Weinberger MD. Natriuretic response to saline infusion in normotensive and hypertensive man. Circulation 55: 779-784, 1977.
29. Luft FC, Rankin LI, Henry DP, Bloch R, Grim CE, Weyman AE, Murray RH, and Weinberger MH. Plasma and urinary norepinephrine values at extremes of sodium intake in normal man. Hypertension 1: 261-266, 1979.
30. MacGregor GA, Fenton S, Alaghband-Zadeh J, Markandu ND, Roulston JE, and deWardener HE. An increase in a circulating inhibitor of Na,K-dependent ATPase: a possible link between salt intake and the development of hypertension. Clin Sci 61: 17s-20s, 1981.
31. Manunta P, Evans G, Hamilton BP, Gann D, Resau J, and Hamlyn JM. A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor (Abstract). J Hypertens 10: S27, 1992.
32. Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, and Bianchi G;. Salt sensitivity study group of theItalian Society of Hypertension. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38: 198-203, 2001.
33. Manunta P, Rogowski AC, Hamilton BP, and Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J Hypertens 12: 549-560, 1994.
34. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, Hamlyn JM, and Bianchi G. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34: 450-456, 1999.
35. Masugi F, Ogihara T, Hasegawa T, Sakaguchi K, and Kumahara Y. Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adrenals. J Hum Hypertens 2: 409-420, 1988.
36. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, and Ludens JH. Mass spectral characterization of an endogenous digitalis-like factor from human plasma. Hypertension 17: 930-935, 1991.
37. Moreth K, Kuske R, Renner D, and Schoner W. Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump. Klin Wochenschr 64: 239-244, 1986.
38. Moreth K, Renner D, and Schoner W. A quantitative receptor assay for digitalis-like compounds in serum. Demonstration of raised concentrations in essential hypertension and correlation with arterial pressure. Klin Wochenschr 65: 179-184, 1987.
39. Morgan T, Carney S, and Myers J. Sodium and hypertension: A review of the role of sodium in pathogenesis and the action of diuretic drugs. Pharmacol Ther 9: 395-418, 1979.
40. Pamnani MB, Bryant HJ, and Haddy FJ. Humoral sodium transport inhibitor in acute volume expansion and low renin hypertension. Hypertension 10: I78-I83, 1987.
41. Pamnani MB, Burris JF, Jemionek JF, Huot SJ, Price M, Freis ED, and Haddy FJ. Humoral Na-K pump inhibitory activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 2: 524-531, 1989.
42. Poston L, Sewell RB, Wilkinson SP, Richardson PJ, Williams R, Clarkson EM, MacGregor GA, and de Wardener HE. Evidence for a circulating sodium transport inhibitor in essential hypertension. Brit Med J 282: 847-849, 1981.
43. Rose BD. Diuretics. Kidney Int 39: 336-352, 1991.
44. Rossi G, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, and Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone, and blood pressure levels. J Hypertens 13: 1181-91, 1995.
45. Rowe JW, Andres R, Tobin JD, Norris AH, and Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155-163, 1976.
46. Schaeffer JS, Talarschik J, Koch KM, Rogowski AC, Manunta P, and Hamlyn JM. Increased plasma levels of ouabain-like compound in dialysis patients: relationship with interdialytic voulme changes (Abstract). J Am Soc Nephrol 2: 348, 1991.
47. Seldin R, Margolies MN, and Smith TW. Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther 188: 615-623, 1974.
48. Smith TW and Haber E. Digitalis (Third of four parts). N Engl J Med, 289: 1063-1072, 1974.
49. Songu-Mize E, Bealer SL, and Hassid AI. Centrally administered ANF promotes appearance of a circulating sodium pump inhibitor. Am J Physiol Heart Circ Physiol 258: H1655-H1659, 1990.
50. Stamler J, Rose G, Elliot P, Dyer A, Marmot M, Kesteloot H, and Stamler R. Findings of the international cooperative INTERSALT study. Hypertension 17(Suppl. I): I-9-I-15, 1991.
51. Strobach H, Wirth KE, and Rojsathaporn K. Absorption and elimination of strophanthus glycosides in man. Naunyn-Schmiedebergs Arch Pharmacol 334:496-500, 1986.
52. Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, Bianchi G, and Manunta P. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 21: 1475-1481, 2003.
53. Yuan C, Manunta P, Hamlyn JM, Chen S, Bohen E, Yeun J, Haddy FJ, and Pamnani MB. Long-term ouabain administration produces hypertension in rats. Hypertension 22: 178-187, 1993.